Abstract:A double-blind placebo-controlled study of bunazosin for the treatment of symptomatic prostatism is reported, incorporating urologic departments of 25 hospitals. Four different doses of bunazosin hydrochloride was administrated orally to 174 patients having benign prostatic hyperplasia and 31 with bladder neck contracture for a period of four weeks; high dose group (45 patients, 3 mg/day for the first week followed by 4.5 mg/day for the next three weeks), middle dose group (45 patients, from 1.5 mg/day for the first week to 3.0 mg/day for the next three), low dose group (39 patient, 0.15 mg/day for the first to 1.5 mg/day for the next three) and a control group (40 patients, 0.125 mg/day for the entire four weeks). Subjective symptoms (urinary frequency, retarded urination, prolonged urination, condition of urinary stream and abdominal pressure at voiding) and objective signs (residual ratio, maximum and mean flow rate, voiding time) were observed and analyzed statistically. No bias in the background features was confirmed between any of the four groups. The subjective improvement rates evaluated by the attending doctors demonstrated a significant dose-dependent efficacy of bunazosin by H-test (p less than 0.01), although the objective improvement rates revealed no significant difference between any of the four groups. The global improvement rate evaluated by the same means demonstrated that the middle dose group was significantly superior to the control group (p less than 0.05 by U-test). According to each subjective symptom evaluated by the criteria of the drug efficacy, a dose-dependent significant (p less than 0.01) was noticed between the four groups in the improvement of the voiding condition. Although there was no significant difference by use of the H-test, the middle dose group had a significant superiority to the control group in the improvement rate of retarded voiding by use of the U-test (p less than 0.05). Only in the symptomatic cases of prolonged voiding, were dose-dependent significant differences observed between all four groups by use of the H-test (p less than 0.05). On the other hand, there was no significant difference between the four groups in the subjective or global improvement rates. Judging from the real data and the graded classification of objective signs, the high and middle dose groups were significantly superior to the control in terms of voiding time, and the high and low dose groups were the same as the control for residual urine ratio.(ABSTRACT TRUNCATED AT 400 WORDS)

Impact of Α-Blocker Therapy on Symptoms of Benign Prostatic Hyperplasia

Personalized Therapeutics of &Amp;alpha;1-Blockers In&nbsp;patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia

The Efficacy and Safety of Alpha-1 Blockers for Benign Prostatic Hyperplasia: an Overview of 15 Systematic Reviews

The inlfuence of prostatic urethral angle on nocturia symptom of the treated BPH patients with α-Receptor blockers

Effect of Self-Management on Lower Urinary Tract Symptoms and Life Quality of Benign Prostatic Hyperplasia Patients

Α1a-Blockers Combination with Antibiotics for the Treatment of Chronic Prostatitis

The efficacy of α1-adrenergic receptor blocker, 5α-reductase inhibitor or combination therapy in benign prostatic hyperplasia

The efficacy and safety of alpha-1 blockers for benign prostatic hyperplasia: an overview of 15 systematic reviews.

Therapeutic Effect of Harnal and Proscar in Treating Benign Prostatic Hyperplasia

Comparison of Different Drugs on the Treatment of Benign Prostate Hyperplasia

Intravesical prostatic protrusion predict the response to α-blocker in patients with BPH

Systematic Review and Meta-Analysis on Phosphodiesterase 5 Inhibitors and Α-Adrenoceptor Antagonists Used Alone or Combined for Treatment of LUTS Due to BPH

The comparison between finasteride and tamsulosin therapeutic efficacy in the treatment of symptomatic benign prostate hyperplasia

Comparison of α1-blocker monotherapy with α1-blocker and antimuscarinics add-on therapy for the treatment of overactive bladder secondary to BPH

IMPACT OF INTERVENTIONAL THERAPY FOR BENIGN PROSTATIC HYPERPLASIA ON QUALITY OF LIFE AND SEXUAL FUNCTION: A PROSPECTIVE STUDY

[A double-blind trial on the effect of alpha-adrenergic blocker (bunazosin hydrochloride) in the symptomatic treatment of prostatism]

Efficacy and Safety of Initial Combination Treatment of an Alpha Blocker with an Anticholinergic Medication in Benign Prostatic Hyperplasia Patients with Lower Urinary Tract Symptoms: Updated Meta-Analysis

Clinical study of prostatic artery embolization combined with tamsulosin capsules in the treatment of benign prostatic hyperplasia

Comparative Effectiveness and Safety of Monodrug Therapies for Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: A Network Meta-analysis

[Progress in the Studies of Alpha1-Receptor Blocker for Benign Prostatic Hyperplasia].

Α1-Blockers for the Reduction of Ureteric Stent-Related Symptoms: A Systematic Review and Meta-Analysis